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Abstract Primary biliary cirrhosis (PBC) is an immune-
mediated chronic cholestatic liver disease with a slowly
progressive course. Without treatment, most patients even-
tually develop fibrosis and cirrhosis of the liver and may
need liver transplantation in the late stage of disease. PBC
primarily affects women (female preponderance 9–10:1)
with a prevalence of up to 1 in 1,000 women over 40 years
of age. Common symptoms of the disease are fatigue and
pruritus, but most patients are asymptomatic at first
presentation. The diagnosis is based on sustained elevation
of serum markers of cholestasis, i.e., alkaline phosphatase
and gamma-glutamyl transferase, and the presence of
serum antimitochondrial antibodies directed against the
E2 subunit of the pyruvate dehydrogenase complex.
Histologically, PBC is characterized by florid bile duct
lesions with damage to biliary epithelial cells, an often
dense portal inflammatory infiltrate and progressive loss
of small intrahepatic bile ducts. Although the insight into
pathogenetic aspects of PBC has grown enormously
during the recent decade and numerous genetic, environ-
mental, and infectious factors have been disclosed which
may contribute to the development of PBC, the precise
pathogenesis remains enigmatic. Ursodeoxycholic acid
(UDCA) is currently the only FDA-approved medical
treatment for PBC. When administered at adequate doses
of 13–15 mg/kg/day, up to two out of three patients with
PBC may have a normal life expectancy without addi-
tional therapeutic measures. The mode of action of UDCA
is still under discussion, but stimulation of impaired hepato-
cellular and cholangiocellular secretion, detoxification of
bile, and antiapoptotic effects may represent key mech-
anisms. One out of three patients does not adequately
respond to UDCA therapy and may need additional
medical therapy and/or liver transplantation. This review
summarizes current knowledge on the clinical, diagnostic,
pathogenetic, and therapeutic aspects of PBC.
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Introduction
Primary biliary cirrhosis (PBC) [1] is an immune-mediated
chronic progressive inflammatory liver disease that leads to
the destruction of small interlobular bile ducts, progressive
cholestasis, and, eventually, fibrosis and cirrhosis of the
liver without medical treatment commonly necessitating
liver transplantation. Addison and Gull [2] have first
described a disease with a PBC-like picture in 1851, but
the term “primary biliary cirrhosis” was coined in 1949
when a cohort of 18 patients with characteristic features of
PBC was published [3]. PBC, predominantly affecting
middle-aged women, is characterized by biochemical
markers of cholestasis, serum antimitochondrial autoanti-
bodies (AMA), and lymphocytic infiltration of the portal
tracts of the liver [4]. Histologically, the hallmark of the
disease is damage to biliary epithelial cells (BEC) and loss
of small intrahepatic bile ducts accompanied by signifi-
cant portal tract infiltration with CD4 and CD8 T cells,
B cells, macrophages, eosinophils, and natural killer cells
[5, 6].
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Being one of the first conditions in which specific
autoantibodies were recognized, PBC is regarded as a
“model autoimmune disease.” Both environmental factors
and inherited genetic predisposition appear to contribute to
its pathogenesis [7]. Although there has been tremendous
progress in unraveling potential pathophysiologic factors in
PBC over the past years [7], the actual impact of each of the
identified genetic and environmental associations is still
controversial. It is the aim of this article to review the
current knowledge of major pathologic features in PBC and
to try to combine these findings to an overall picture of the
pathogenesis of PBC.
The most frequent symptoms in PBC are fatigue and
pruritus, occurring in up to 85% and 70% of patients,
respectively [8, 9]. Median survival in untreated individuals
has been reported to be 7.5 to 16 years [1, 10], but has
largely improved since the introduction of ursodeoxycholic
acid (UDCA) therapy and liver transplantation. Patients that
are treated with UDCA at an early stage of the disease and
respond well to therapy may reach normal life expectancy
[11–14]. However, the beneficial mechanisms of UDCA
treatment are still incompletely understood, and about one
third of patients fail to adequately respond to UDCA
monotherapy. In the second part of this review, we will
therefore summarize the rationale behind UDCA therapy
and give an overview on future therapeutic options
currently under study.
Epidemiology
PBC occurs in individuals of all ethnic origins and accounts
for up to 2.0% of deaths from cirrhosis [15]. It primarily
affects women with a peak incidence in the fifth decade of
life, and it is uncommon in persons under 25 years of age.
Incidence and prevalence vary strikingly in different
geographic regions (as does the quality of epidemiological
studies related to PBC), ranging from 0.7 to 49 and 6.7 to
402 per million, respectively [16–23]. The highest inci-
dence and prevalence rates are reported from the UK [16,
21], Scandinavia [17], Canada [18], and the USA [19, 22],
all in the northern hemisphere, whereas the lowest was
found in Australia [20]. There is no clear evidence to
support or exclude the concept of “a polar–equatorial
gradient,” as it has been reported for other autoimmune
conditions [24].
Diagnosis
Increased awareness of the condition and the increasing
availability of diagnostic tools, in particular serological
testing, have led to a more frequent and earlier diagnosis of
PBC [25]. More than half of patients diagnosed today with
PBC are asymptomatic at presentation [26, 27]. They
generally attract attention by findings of elevated serum
alkaline phosphatase (AP) and/or total serum cholesterol,
especially in asymptomatic patients often during routine
checkup. A diagnosis of PBC is made “with confidence”
when biochemical markers of cholestasis, particularly alkaline
phosphatase, are elevated persistently for more than 6 months
in the presence of serum AMA and in the absence of an
alternative explanation [28, 29]. In PBC patients, AMA is
generally present in high titer. Low-titer AMA may not be
specific and may disappear on retesting [30].
Compatible histological findings confirm the diagnosis
and allow staging before therapeutic intervention, but in
many cases, histological workup is not necessary to
diagnose PBC [29].
Biochemical tests
Serum AP and γGT are commonly elevated and define,
together with AMA, the diagnosis of PBC. Mildly elevated
serum aminotransferases (ALT, AST) are usually observed
in PBC but are not diagnostic. Increased serum levels of
(conjugated) bilirubin as well as alterations in prothrombin
time and serum albumin are late phenomena in PBC like in
other cirrhotic states and unusual at diagnosis. However,
serum bilirubin is a strong and independent predictor of
survival [31] with a high impact on all established models
for prognosis.
Serum cholesterol is commonly elevated in patients with
PBC, alike other cholestatic conditions. The increased
cholesterol level in PBC is largely caused by the presence
of LpX [32]. LpX is an abnormal lipid particle which is
characteristic for cholestatic liver disease and that is directly
derived from biliary lipids that regurgitate into the blood
[33]. Upon lipoprotein fractionation, LpX is usually
found in the very low-density lipoprotein fraction but is
very different from other lipoproteins. In contrast to
normal lipoproteins, which have a core filled with neutral
lipid, LpX consists of liposomes (with an aqueous lumen)
of phospholipids and free cholesterol. LpX is not taken
up in atherosclerotic plaques and may reduce the
atherogenicity of low-density lipoprotein (LDL) choles-
terol by preventing LDL oxidation [34]. Accordingly, the
increased serum cholesterol in PBC patients is not
associated with increased risk for cardiovascular disease.
In contrast, long-lasting PBC is associated with the
occurrence of xanthomata and xanthelasma. Hypercholes-
terolemia in PBC patients is responsive to statin treatment.
Long-term treatment with UDCA also reduces serum
cholesterol [35].
Though not diagnostic, thyroid-stimulating hormone
levels should be assessed in any patient who is believed
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to have PBC due to the high association of PBC with
thyroid dysfunction, mainly caused by Hashimoto
thyroiditis.
Serology
AMA autoantibodies are pathognomonic for PBC and lead
to the diagnosis with a high specificity and sensitivity.
AMA-positive individuals, even if no signs of cholestasis
and/or liver inflammation are present, are very likely to
develop PBC. Mitchison et al. [36], in a small study,
evaluated liver pathology of 29 asymptomatic AMA-
positive (levels>1:40) individuals lacking AP elevation.
At inclusion, all but two had abnormal liver histology, and
in 12, findings were diagnostic for PBC. A 10-year follow-
up of these subjects revealed that 24 of the 29 remained
AMA-positive; all 24 developed biochemical evidence of
cholestasis and 22 became symptomatic [37], confirming a
high positive predictive value of positive AMA testing for
the development of PBC.
Sensitivity of AMA, however, although high, is limited.
Investigators have reported patients who clinically, bio-
chemically, and histologically have all the features of PBC
despite consistently negative AMA testing both by immu-
nofluorescence and with the most specific immunoblotting
and immunoenzymatic techniques [38–42]. Overall, AMA
seems to be negative in 5% of patients who otherwise have
all the features typical for PBC [43] and an identical
autoreactive CD4 T cell response to the critical autoantigen,
PDC-E2 [44]. This small group of AMA-negative patients,
however, may erroneously include patients with PBC-like
symptoms induced by causes other than autoimmunity,
such as patients with mutations in the ABCB4 (MDR3) gene
[45]. These patients secrete reduced amounts of phospho-
lipids into the bile, which is harmful to hepatocytes and
cholangiocytes.
The pattern of serum immunoglobulin fractions in PBC
is characterized by an elevation of serum IgM [46],
possibly due to an abnormal chronic B cell activation by
Toll-like receptor-dependent signaling [47]. However, spec-
ificity of this finding is limited and IgM levels are not
commonly used as a diagnostic criterium.
Nonspecific antinuclear antibodies (ANA) and/or
smooth muscle antibodies are found in serum of one third
of patients with otherwise clear-cut PBC [48], but are of
limited diagnostic value. In contrast, specific ANA directed
against nuclear body or envelope proteins such as anti-
Sp100, presenting as multiple (6–12) nuclear dots at
indirect immunofluorescence staining and anti-gp210,
presenting as perinuclear rims have shown a specificity
of >95% for PBC, although their sensitivity is low. These
specific ANA can be used as diagnostic markers for PBC in
the absence of AMA titers [29].
Imaging
Ultrasound examination of the liver and biliary tree is
obligatory in all cholestatic patients in order to differentiate
intrahepatic from extrahepatic cholestasis. When the biliary
system appears normal and serum AMA are present, no
further radiologic workup is necessary. Abdominal lymph-
adenopathy, particularly in the hilar region of the liver, is
seen in 80% of patients with PBC [49].
Transient elastography (TE) has been introduced as a
new, simple and noninvasive imaging technique for
determining the degree of fibrosis in patients with chronic
liver diseases, mainly chronic hepatitis C [50]. Corpechot et
al. [51] compared liver stiffness as determined by TE
(FibroscanR) to histological findings obtained by liver
biopsy in 101 patients with PBC (n = 73) or primary
sclerosing cholangitis (PSC; n = 28) and showed a highly
significant correlation of liver stiffness with both degree of
fibrosis and histological stage. Further studies in indepen-
dent cohorts of PBC patients are warranted before TE can
be regarded as an established alternative to liver biopsy in
the staging of chronic cholestatic liver disease. Still, TE
appears attractive as a screening tool in future therapeutic
trials, as it may help overcome the limited staging accuracy
of liver biopsy due to heterogeneous distribution of
inflammation and fibrosis in PBC.
Liver biopsy/histology
A liver biopsy is not anymore regarded as mandatory for
the diagnosis of PBC in patients with elevated serum
markers of cholestasis and positive serum AMA [28, 29],
but may be helpful in excluding other potential causes of
cholestatic disease and in assessing disease activity and stage.
A liver biopsy may also be helpful in the presence of
disproportionally elevated serum transaminases and/or serum
IgG levels to identify additional or alternative processes.
Histological staging of PBC (stage 1 to stage 4) is determined
by the degree of (peri)portal inflammation, bile duct damage
and proliferation, and the presence of fibrosis/cirrhosis
according to Ludwig et al. [52] and Scheuer [53]. Stage 1
disease is characterized by portal inflammation with granu-
lomatous destruction of the bile ducts, although granulomas
are often not seen. Stage 2 is characterized by periportal
hepatitis and bile duct proliferation. Presence of fibrous septa
or bridging necrosis is defined as stage 3 and cirrhosis as
stage 4 [52]. Findings of fibrotic or cirrhotic changes (stage 3
or 4) are accompanied by a worse prognosis [54]. Florid duct
lesions as defined by focal duct obliteration and granuloma
formation are regarded as typical for PBC. The liver is not
uniformly involved, and features of all four stages of PBC
can be found in one biopsy specimen. The most advanced
histological features are used for histological staging.
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Clinical findings
At diagnosis, the majority of patients are asymptomatic and
present e.g. for workup of elevated serum levels of AP or
cholesterol [55, 56]. In symptomatic patients, fatigue and
pruritus are the most common complaints and have been
reported in 21% and 19% of patients at presentation,
respectively [27, 57]. Unexplained discomfort in the right
upper quadrant of the abdomen has been reported in
approximately 10% of patients [58]. In the majority of
asymptomatic and untreated patients, overt symptoms
develop within 2 to 4 years, although one third may remain
symptom-free for many years [27, 56].
Fatigue
During the course of the disease, up to 80% of PBC
patients complain of chronic fatigue impairing quality of
life and interfering with daily life activities [8, 59]. No
correlation with the severity of the liver disease could be
demonstrated [59], but there is an association with
autonomic dysfunction (in particular orthostatic hypoten-
sion) [60], sleep disturbance and excessive daytime
somnolence [60], and, although weak, depression [61],
which might necessitate treatment for themselves. The
exact pathophysiological mechanisms leading to chronic
fatigue in PBC and other cholestatic diseases are not
unraveled so far. Standard therapy of PBC with UDCA
and even liver transplantation may fail to improve this often
disabling symptom.
Pruritus
PBC is more frequently associated with pruritus than other
chronic cholestatic liver diseases. During the course of the
disease, pruritus occurs in 20% to 70% of patients and can
often be the most distressing symptom [62]. It develops
independently of the degree of cholestasis and the stage of
disease. Its pathogenesis remains poorly understood and the
potential pruritogens in cholestasis are undefined. The
therapeutic efficacy of anion exchange resins like
cholestyramine, the pregnane X receptor agonist, rifam-
picin, plasmapheresis, and albumin dialysis as well as
nasobiliary drainage led to the conclusion that in
cholestasis putative pruritogens accumulate in the circu-
lation, are secreted into bile, and undergo an enter-
ohepatic cycle. Itch could then be induced locally in the
skin or in neuronal structures. Bile salt metabolites,
progesterone metabolites, histamine, and endogenous
opioids, among others, have all been proposed as
causative agents. However, evidence for a key role of
any of these suggested pruritogens in cholestasis is weak
[63].
Portal hypertension
Variceal hemorrhage or other signs of portal hypertension
secondary to fibrosis or cirrhosis are uncommon at first
presentation, but have occasionally been described [64].
However, portal hypertension as determined by measure-
ment of the portohepatic pressure gradient (PHG) is
common in PBC, and a stable or - under treatment -
improved PHG is a predictor of survival [65, 66].
Metabolic bone disease
Patients with PBC have been reported to be at increased
risk of osteoporosis in some studies [67], but reports in the
literature remain contradictory. Patients with advanced PBC
may be at particular risk for osteoporosis and may present
with osteoporosis and yet be otherwise asymptomatic from
their liver disease. The development of osteoporosis in PBC
patients has been attributed to both, decreased osteoblast
activity and increased osteoclast activity [68]. Metabolism
of vitamin D is normal in PBC, but malabsorption of both
calcium and vitamin D may occur predominantly in late-
stage disease. Pancreatic insufficiency and celiac disease,
which are associated with PBC [69–71], may further
aggravate malabsorption.
Fat-soluble vitamin malabsorption
When secretion of bile and bile salts is insufficient, i.e., bile
salts drop below the critical micellar level in the duodenum,
malabsorption of both fat and fat-soluble vitamins may
ensue. Serum levels of vitamin A and E have been shown
to be low in a minority of patients with primary biliary
cirrhosis prior to development of jaundice [72]. Osteoma-
lacia is barely seen in PBC, as a liver transplant is
performed in most patients before the development of this
complication of prolonged deep jaundice.
Urinary tract infections
Though often asymptomatic, recurrent urinary tract infec-
tions have been reported in up to 19% of women with PBC
[73], and a potential pathophysiologic relevance of Escher-
ichia coli strains has been suggested.
Malignancy
Reports on the rate of breast carcinoma in women with
PBC differ and reported either an increase in risk [74, 75]
or equal risk [18, 76] compared to a healthy population.
Hepatocellular carcinoma in late-stage PBC has been
reported to occur at rates similar to other kinds of cirrhosis
[77–79], but seems to be more frequent in men with PBC:
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One study reported an average HCC prevalence of 5.9% in
advanced PBC (4.1% in women but 20% in men) [77].
Associated disorders
A number of mostly immune-mediated diseases are
commonly observed in patients with PBC. Thyroid dys-
function is frequently associated with PBC, often predating
its diagnosis [80]. Sicca syndrome is seen in up to 70% of
patients [81]. Incomplete or complete CREST syndrome
(calcinosis cutis, Raynaud syndrome, esophageal motility
disorder, sclerodactyly, teleangiectasia) is not uncommon
[82]. Celiac disease has been reported in up to 6% of
patients [72] and is by far more commonly associated with
PBC than inflammatory bowel diseases [83].
Pathogenesis
A florid bile duct lesion with damage to BEC and
subsequent destruction of small bile ducts is the histopath-
ologic hallmark of PBC. The exact pathogenetic mecha-
nisms responsible for BEC damage in PBC remain
unknown. Increasing experimental evidence, however,
suggests that the florid bile duct lesion in PBC is initiated




Genetic factors have an impact on PBC pathogenesis that is
stronger than that in nearly any other autoimmune disease
[85–87]. Accordingly, a concordance rate of about 60% was
seen in monozygotic twins (as opposed to nearly 0% for
dizygotic twins) [88, 89]. A significantly increased inci-
dence of PBC is seen in relatives of PBC patients [89, 90].
The relative risk of a first-degree relative of a PBC patient
is 50- to 100-fold higher than for the general population
[91], yielding a prevalence rate up to 5–6% [19, 90, 92].
Interestingly, among affected monozygotic twins, though
the age of disease onset is similar, progression and disease
severity vary, emphasizing the role of epigenetic and
probably environmental factors [89].
It has been difficult to identify distinct susceptibility
genes in PBC so far. Genetic associations in PBC were
shown with major histocompatibility complex encoded
genes. PBC is apparently associated with the DRB1*08
family of alleles, although marked variation is observed
between different ethnic groups. Association with the
DRB1*0801-containing haplotype is seen in populations
of European origin, whereas in populations of Asian origin,
an association is seen with the DRB1*0803 allele. A
protective association has been described with DRB1*11
and DRB1*13, but once again, significant population
differences are observed [93–102]. Both associations of
PBC with the DRB1*08 allele as well as the protective
association of DRB1*11 and DRB1*13 were recently
confirmed in the largest series ever reported including 664
unrelated patients from Italy [103]. The odds ratio for
developing PBC was 3.3 for DRB1*08-positive subjects,
whereas it was reduced to 0.3 for subjects positive for
DRB1*11, to 0.7 for DRB1*13, and to 0.1 for carriers of
both DRB1*11 and DRB1*13. This study again highlight-
ed the relevance of geographic variation, with marked
differences in allele association between northern and
southern Italy.
Associations have also been reported with polymor-
phisms of genes involved in innate or adaptive immunity.
Allelic variations of tumor necrosis factor α (TNFα) and of
cytotoxic T lymphocyte antigen 4 (CTLA-4), a key
regulator of the adaptive immune system, have been
repeatedly associated with susceptibility to different auto-
immune diseases (such as type I diabetes mellitus and
systemic lupus erythematosus) and were also associated
with PBC [104–109]. Although an association of CTLA-4
variants and susceptibility to PBC could not be demon-
strated in all studies [110, 111], Poupon et al. [112] most
recently confirmed a potential role of TNFα and CTLA-4
variants in the pathogenesis of PBC. In 258 PBC patients
and two independent control groups of 286 and 269 healthy
volunteers, the authors investigated distribution of newly
identified htSNPs of 15 selected candidate genes: two
related to immunity encoding for CTLA-4 and TNFα, ten
genes related to bile formation encoding hepatobiliary
transporters, and three related to adaptive response to
cholestasis encoding nuclear receptors. In a case–control
analysis, only haplotype-tagging single nucleotide poly-
morphisms (htSNPs) in CTLA-4 and TNFα showed differ-
ences in distribution between PBC and controls, confirming
their potential role in the pathogenesis of PBC. In contrast,
htSNPs of the ten transporter genes as well as the three
nuclear receptor genes under study were equally distribut-
ed, confirming previous studies of htSNPs in key trans-
porters without major impact [1, 113, 114]. A strong
association of the allelic variant TNFα rs 1799724 (C/T)
with disease progression was shown. Most interestingly, a
strong association with disease progression was also shown
for AE2 rs 2303932 (T/A), a gene encoding for the apical
anion exchanger 2 (AE2) in cholangiocytes and hepato-
cytes. In both cases, presence of the variant was associated
with delayed disease progression. In a multi-variate Cox
regression, the AE2 variant rs2303932 (T/A) was an
independent prognostic factor for disease progression in
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PBC under UDCA treatment, in addition to serum bilirubin,
alkaline phosphatase, and serum albumin levels which are
established surrogate markers of prognosis in PBC [112].
Most recently, a landmark genetic association study was
published [332]. Associations with the risk of disease were
unravelled for 13 loci across the HLA class II region, two
SNPs at the interleukin 12 alpha (IL12A) locus, one SNP at
the interleukin 12 receptor beta 2 locus, and one previously
described SNP at the CTLA4 locus. Associations with more
than 10 further loci were described. Various associations
with other loci have been described in individual populations,
mostly of limited size. However, the vast majority have not
been confirmed in independent cohorts, and to date, none of
the genetic associations described in PBC have been proven
sufficiently [84, 88, 108].
Future genetic linkage studies in affected families as well
as association studies in large cohorts of unrelated patients
may disclose genetic variants conferring susceptibility or
influencing progression and severity of disease. Such
linkage studies are awaited for PBC [115].
It remains speculative whether the female preponder-
ance (gender ratio up to 10:1) reflects an X-chromosome-
linked locus of susceptibility. Alternatively, a protective
role of Y-linked genes could be assumed, or just a
gender-specific exposure to environmental triggers like
cosmetics [116] or nail polishers [117], as discussed below.
However, speculation on a pathomechanistic role for X
chromosomal genes was supported by the observation of
an increased frequency of X chromosome monosomy in
PBC as well as in other autoimmune diseases. This
increase in X chromosome monosomy might lead to
haploinsufficiency for specific X-linked genes and thereby
increase disease predisposition [118]. Case reports of PBC
in patients with Turner syndrome (45, X0) also supported
this hypothesis [119].
Estrogen signaling has also been proposed to play a role
in the homeostatic proliferative response of cholangiocytes
in PBC. Accordingly, studies on polymorphisms in estrogen
receptor genes revealed associations with the disease, at
least in some populations [120]. At the tissue level,
cholangiocytes from PBC patients in the earliest disease
stages (but not cholangiocytes from normal controls)
express estrogen receptors [121]. Agents able to modulate
estrogen-receptor-mediated responses (such as tamoxifen)
have therefore been proposed as novel, BEC homeostasis
targeting therapies, and case reports support this hypothesis
[122, 123], but as yet, this potentially interesting therapeu-
tic approach has not undergone formal assessment in
clinical trials.
Most recently, altered expression of hepatic microRNA
(miRNA) has been described in liver tissue of PBC patients
[124]. Certain miRNA negatively regulate protein coding
gene expression and may play a critical role in various
biological processes. However, a causal link between
altered miRNA expression and the development of PBC
still remains unproven.
Environmental factors
Despite strong evidence for a genetic background in
PBC, epidemiological studies have early suggested a
role for environmental factors in triggering and/or
exacerbating PBC [20, 125, 126]. A significant role for
environmental factors was supported by the identification
of geographic disease “hot spots,” as first reported in the
northeast of England, using formal cluster analysis. The
original UK analysis reported an increased frequency of
PBC in former industrial and/or coal mining areas [127].
Another recent study from New York examined the
prevalence of PBC and PSC near superfund areas and
reported significant clusters of PBC surrounding toxic
sites [128]. In synopsis, these observations gave rise to the
hypothesis of a chemical environmental factor, potentially
associated with contaminated land, which could either
trigger disease or cause disease through a direct toxic
effect [84]. This hypothesis would also provide one
possible explanation for the tissue tropism of PBC if the
toxin or toxins are excreted into bile (and thereby
concentrated in the biliary tree) [84]. The observation that
hormone replacement therapy and frequent use of nail
polish are linked to the risk of developing PBC further
supports the potential impact of environmental factors in
the pathogenesis of PBC [117]. Smoking also seems to be
a risk factor for PBC and has been demonstrated to
accelerate progression [117, 129]. Associations of expo-
sure to chemical environmental compounds and xeno-
biotics (including drugs, pesticides, or other organic
molecules) with various human autoimmune diseases have
been described as summarized in [86].
Xenobiotics may contribute to the pathogenesis of PBC
by triggering autoimmune reactions. Different mechanisms
for the induction of autoimmunity by xenobiotics have been
proposed [86, 130]. A potential direct toxic effect of
xenobiotics my cause cell death by apoptosis or oncosis,
inducing the generation of immunogenic autoepitopes. In
addition, chemical modification of native cellular proteins
by removal and/or exchange of a hapten has been shown to
change processing in antigen-presenting cells and may lead
to the presentation of cryptic, potentially immunogenic
peptides. Furthermore, xenobiotics may have the potential
to modify host proteins to form neoantigens. Neoantigen-
specific T cells and B cells, once primed, may cross-react
with the formerly inert native autoantigens. In accordance
with this hypothesis, Amano et al. [131] studied a number
of xenobiotics with a structure similar to lipoic acid, a
residue on the E2 epitope of the pyruvate dehydrogenase
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complex (PDC-E2), the main autoreactive antigen identi-
fied in PBC so far in PBC. Replacement of lipoic acid by
certain xenobiotics enhanced the reactivity of PBC sera
against the PDC-E2 epitope. Particularly, one of the
xenobiotics, 2-nonynoic acid, induced reactivity of PBC
sera stronger than that of the native lipoic acid residue.
Interestingly, the methyl ester of 2-nonynoic acid has a
viol-/peach-like scent and is used as an ingredient in
perfumes. It is ranked 2,324th out of 12,945 chemical
compounds in terms of occupational exposure with an 80%
female preponderance due to its use in cosmetics.
Infections
Among the environmental factors that have been sug-
gested as potential causative agents in PBC, particularly
different bacteria have been discussed. In early histologic
lesions in PBC, non-caseating granulomas are observed,
as seen in other granulomatous liver diseases including
sarcoidosis [1], drug reactions, and, most interestingly,
infections. Furthermore, non-caseating granulomas are
unique to PBC when compared to other autoimmune
pathologies. This has led to suspicion of a microbial basis
for PBC [132]. In support of this hypothesis, certain
bacteria were found to contain PDC components fully
cross-reactive with the mammalian form. It was proposed
that exposure to these homologues could trigger cross-
reactive immunity. In favor of a bacterial etiology, recent
data suggest that Toll-like receptor ligands induce an
augmented inflammatory response in PBC. In combina-
tion, presence of cross-reactive antigens in a pro-
inflammatory environment would theoretically be able to
break tolerance [133, 134].
With this theoretical background in mind, early studies
associating various bacteria with PBC re-attract interest: E.
coli has been reported to be present in excess in the feces of
patients with PBC. In addition, the incidence of urinary
tract infections often induced by E. coli is high in PBC
patients [73, 135], and history of urinary tract infections
increases the risk of PBC [117]. Another microorganism
that has been proposed as a candidate for the induction of
PBC is Novosphingobium aromaticivorans [136]. Titers of
antibodies against lipoylated bacterial proteins of this
ubiquitous organism, which metabolizes organic com-
pounds including estrogens, were 1,000-fold higher com-
pared to those against E. coli in patients with PBC, but no
antibodies were observed in a large cohort of healthy
subjects. Lactobacilli and Chlamydia, which show some
structural homology with the autoantigen (although reac-
tivity against them is considerably less than that against
either E. coli or N. aromaticivorans), have also been
implicated as putative pathogens, as have Helicobacter
pylori and Mycobacterium gordonae [137–140]. Recently, a
case of PBC following lactobacillus vaccination for
recurrent vaginitis was reported. The vaccine contained
Lactobacillus salivarius, which exerts a high homology to
the beta-galactosidase of Lactobacillus delbrueckii
(LACDE BGAL266–280), and cross-reactivity of patients'
autoantibodies against the human PDC-E2212–226 epitope
and LACDE BGAL266–280 was found. Affinity to the
Lactobacillus epitope was higher than to the native
mammalian, suggesting that antimicrobial reactivity may
have preceded that to the self-mimic [141]. However, the
AMA status of this patient before repetitive lactobacillus
vaccination could not be assessed and causal relation of
lactobacillus exposure and development of PBC remains
speculative also in this study.
Despite these intriguing associations, no compelling data
have been provided to show that one individual infectious
agent can reproducibly be detected in patients with PBC.
Although attractive, the model of bacterial infections as
cause of PBC is thus supported by little direct evidence.
Further objective data are warranted, obtained either from
prospectively followed cohorts or through case–control
epidemiological approaches, confirming a role for bacteria
in triggering PBC [84].
An alternative infectious agent has recently been
proposed as trigger of PBC when a human retrovirus was
identified both in liver tissue and hilar lymph nodes from
PBC patients. EM analysis of liver tissue obtained from
PBC patients revealed retrovirus compatible particles in
BECs. In periportal lymph nodes, mouse mammary tumor
virus (MMTV) was detected and correlated with aberrant
distribution of PDC-E2 in perisinusoidal cells. Homoge-
nates of these periportal lymph nodes also had the capacity
to infect BEC cultures inducing marked phenotypic change,
and this effect could be abolished by irradiation of the
culture media, suggestive of an infectious agent [142, 143].
Retroviral infection hypothetically could cause BEC dam-
age either through a direct viral cytopathic effect, through
cross-reactivity between viral protein and self-PDC, a
“molecular mimicry” model, or virus-induced apoptosis
[84]. Retroviral infection would also provide explanations
for some key phenomena in PBC. PBC can recur rapidly
after transplantation with all of the clinical manifestations
including the detection of AMA in serum [144], the
aberrant expression of the AMA-reactive protein on BEC
[145], and histologic evidence of disease in up to 45% of
patients [146]. In this respect, the observation of an
association of more potent immunosuppressive therapy
following transplant and earlier and more aggressive recur-
rence of PBC [147] is also of interest. MMTV replication is
regulated in part by a progesterone-responsive glucocorticoid
regulatory element in the promoter region, offering an
alternative explanation for the female preponderance seen
with PBC [148].
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These findings attracted attention in the field and were
acknowledged by other investigators who pointed out the
need for clinical trials with antiretroviral therapies [149].
Subsequently, in a small non-randomized pilot study,
therapy with Combivir (lamivudine + zidovudine) im-
proved inflammatory scores, normalized AP, and reduced
bile duct injury in patients with PBC [150]. These findings
await confirmation in a randomized, controlled trial.
Unfortunately, major findings of the outlined in vitro
studies could not be reproduced by independent groups,
and others raised concerns that these findings might mainly
reflect contamination or technical artifacts [151]. In an
independent study, a large number of sera of PBC patients
and healthy controls did not show reactivity against MMTV
encoded protein, and no detectable immunohistochemical
or molecular evidence for MMTV was found in liver
specimens or peripheral blood lymphocytes [152]. It was
also speculated that beneficial effects of antiretroviral
therapy could be partly explained by anti-apoptotic proper-
ties of nucleoside analogs [151, 153]. Furthermore, mech-
anisms by which human betaretrovirus would enter human
cholangiocytes are also not identified.
A more recent study, however, strengthened the case for
involvement of retroviruses in (immune-mediated) liver
disease: Sera of 179 patients with diverse chronic liver
diseases and 31 controls were tested for reverse transcrip-
tase activity and presence of human betaretrovirus by
polymerase chain reaction. Reverse transcriptase activity
was detected in 73% of autoimmune hepatitis patients, 42%
of PBC subjects, 35% of patients with viral hepatitis, 22%
of liver patients without viral or autoimmune pathogenesis
(non-alcoholic fatty liver disease and alcoholic liver
disease), and 7% of control subjects. In polymerase chain
reactions, 24% of PBC samples were positive for human
betaretrovirus compared to 13% in autoimmune hepatitis,
5% in other liver diseases, and 3% in non-liver disease
control subjects [154]. If these data can be confirmed, a
retroviral compound in the pathogenesis of immune-
mediated and viral liver disease seems attractive, though
not specific for PBC. Thus, despite some intriguing
findings, the pathogenetic relevance of retroviruses in the
development of PBC remains enigmatic.
Others
Appendectomy, other abdominal surgeries, and tonsillecto-
my were significantly more frequently reported in patients
with PBC in an epidemiological study in North America
[155]. However, an earlier population-based case control
study conducted in England did not show such associations
[156]. More recently, another case–control study provided
evidence that there was at least no association between PBC
and the occurrence of appendectomy and pointed out the
selection bias present in the previous study done in North
America [157]. The linkage to appendectomy was theoret-
ically attractive, since a PBC-specific immune response to
the highly conserved caseinolytic protease P of Yersinia
enterocolitica in 40% of patients with PBC was reported
[158]. It is noteworthy, that infection with Y. enterocolitica
is one of the major causes of acute terminal ileitis
mimicking acute appendicitis [159].
Autoimmunity
Autoimmunity is a phenomenon of dysregulated immune
response against self-antigens. If persistent, this can result
in inflammatory tissue damage. The immune response to
antigens is tightly controlled by various pathways whose
deregulation may lead to autoimmune responses. Genetic
predisposition and environmental factors affect the suscep-
tibility to such deregulation [86].
Tolerance against self- antigens is achieved in the
lymphopoietic differentiation in early life, when high-
affinity self-reactive lymphocytes are deleted in the primary
lymphoid organs, thymus, and bone marrow. Second, in the
periphery, there is activity of a subset of T lymphocytes, T
regulatory cells (Tregs), which are dedicated to regulatory
function expressing the CD4 and CD25 surface markers and
the transcription factor forkhead box P3 (FOXP3). Addi-
tional backups along the maturation process of lymphocytes
are described, limiting the induction and expression of
autoimmunity. These regulatory mechanisms include apo-
ptosis pathways, cytokines and their receptors, chemokine
signaling, T cell–T cell interactions, and intracellular signal
transduction. Accordingly, loss of self-tolerance could
involve multiple faults, most of which are of genetic origin.
It is worth mentioning that autoimmunity, defined by the
presence of autoantibodies and autoreactive lymphocytes
does occur naturally. It appears that such naturally occur-
ring autoantibodies and autoreactive lymphocytes are
modulators for the suppression of early infections, clear-
ance of apoptotic bodies, immune surveillance against cancer
cells, among others, as reviewed in [160]. In this not yet
completely unraveled system regulating immune response,
the mechanisms responsible for the development of autoim-
munity and autoimmune diseases remain enigmatic.
Imbalance of T cell regulation can be sufficient on its
own to initiate or propagate autoimmunity in various
chronic inflammatory diseases such as inflammatory bowel
disease (IBD) or rheumatoid arthritis. In line with this
concept, recent transgenic animal models highlight the role
of T cell regulation in the development of autoimmune
diseases. For instance, IL-2 receptor−/− mice were shown to
develop severe anemia and IBD [161], possibly due to the
decreased numbers of Tregs facilitating autoimmune reac-
tivity in the presence of proliferating (and probably,
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activated) T-cells. Absence of the IL-2 receptor in these
animals leads to proliferation of T cells and decreased
numbers of Tregs.
Another hypothesis is the concept of molecular mimicry
based on the similarity of pathogen and host antigen-
derived epitopes recognized by the immune system [162,
163], which render bacteria and viruses candidates for the
induction of autoimmune disease. This mechanism has first
been suggested to be responsible for the development of
rheumatic fever, and though this could never be confirmed,
there is evidence suggesting associations of infectious
triggers for several systemic autoimmune diseases including
multiple sclerosis [164, 165], systemic lupus erythematosus
(SLE) [166], and rheumatoid arthritis [167]. Autoantigens
are unable to elicit a primary immune response themselves.
However, T cells stimulated by a pathogenic cross-reactive
epitope can recognize such targets. As a prerequisite, the
pathogen-derived cross-reactive epitope has to be suffi-
ciently different from the host-derived epitope. The role of
infectious agents in development of autoimmunity has
recently been reviewed elsewhere [168, 169].
Xenobiotics represent another environmental factor
foreign to human organisms, and may induce immune
reactions or have the potential to modify host proteins and
render them more immunogenic. Examples include drugs,
pesticides, or other organic molecules. A number of
xenobiotics have been associated with several human
autoimmune diseases. Chemicals which were linked to
autoimmunity include mercury in glomerulonephritis [170],
hydrazines in SLE [171, 172], iodine in autoimmune
thyroditis [173], and halothane in drug-induced hepatitis
[174, 175]. Halothane-induced liver disease occurs when
susceptible individuals develop immune response against
trifluoroacetylated (TFA) self-proteins upon halothane
exposure. Noteworthy is that the lipoylated E2 domain of
human PDC is also recognized by anti-TFA [176].
As a further trigger of autoimmunity, it has been
speculated that increased cell turnover or, more specifically,
increased cell apoptosis may lead to exposure of otherwise
rarely exposed antigens and induction of immune response
to self. Enhanced apoptosis has been implicated in several
autoimmune diseases, including Hashimoto's thyreoiditis
[177]. This hypothesis would also provide an appealing
explanation for the tissue specificity of most autoimmune
reactions despite the often ubiquitous expression of the
targeted autoantigen.
However, apoptosis is genuinely designed to actually
prevent inflammatory reactions to cell death, and ingestion
of apoptotic cells by macrophages induces the expression of
anti-inflammatory cytokines such as TGF-β and IL-10,
both promoting the expression of Tregs, suppressing an
autoimmune response during apoptosis [160]. While apo-
ptosis per se is a non-inflammatory process, it can lead to
abnormal antigen presentation, especially of previously
sequestered antigens. Evidence for a role in the develop-
ment of autoimmune disease, however, is limited and
particularly in organ-specific autoimmune diseases [178].
Whether apoptosis-related mechanisms lead to PBC is
unclear [179], but cholangiocytes in PBC may undergo
increased cell turnover, e.g., due to metabolic stress,
resulting in an inadequate immune response [179]. Strik-
ingly, BECs in patients with PBC seem to be under
significantly increased apoptotic stress compared to healthy
controls or patients with other causes of inflammatory
reactions in the liver, such as chronic viral hepatitis or PSC
[180–182]. However, it is yet to be elucidated whether this
effect is really a cause of autoimmunity in PBC or rather
the consequence of increased inflammation.
Loss of self-tolerance in PBC
PBC is associated with other autoimmune diseases, both
within individuals and among families, reflecting the
“clustering” characteristic for autoimmunity [183]. PBC
was one of the first conditions in which the presence of
autoantibodies in the serum was identified and in which the
antigen specificity of this autoreactive response was
characterized [5]. It is therefore often referred to as a
“model autoimmune disease.” The predominant autoreac-
tive antibodies in PBC are AMAs, which, with a high
sensitivity and specificity, are virtually diagnostic for PBC
when detected in serum. The so far identified targets of
AMA are all members of the family of 2-oxo-acid
dehydrogenase complexes (2-OADC). This includes the
E2 subunits of the pyruvate dehydrogenase complex (PDC-
E2), the branched chain 2-oxo-acid dehydrogenase complex
(BCOADC-E2), the 2-oxo-glutaric acid dehydrogenase
complex (OGDC-E2), and the dihydrolipoamide dehydro-
genase binding protein (E3BP) [184], all localized within
the inner mitochondrial matrix, catalyzing oxidative decar-
boxylation of keto acid substrates. The targeted E2 subunits
all have a common N-terminal domain containing single or
multiple attachment sites for a lipoic acid cofactor to lysine.
Previous studies have demonstrated that the dominant
epitopes recognized by AMA are all located within these
lipoyl domains of the target antigens [185–188]. The
autoreactive CD4 and CD8 T cells infiltrating the liver in
PBC recognize the same PDC-E2 domain (peptides 159–
167 and 163–176) [189, 190], and the same accounts for
the dominant autoreactive B cells [191]. CD8 T cells
isolated from livers of patients with PBC have been found
to exert cytotoxicity against PDC-E2 pulsed autologous
cells (peptides 159–167) [192], supporting the hypothesis
of a T cell response contributing to bile duct injury in PBC.
It remains a mystery how PDC-E2 and other epitopes
localized to the inner membrane of mitochondria become
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targets of autoimmune injury in PBC. One working
hypothesis, largely enforced by the Gershwin group, is that
modifications of 2-OADC by xenobiotics may alter these
self-proteins to cause a breakdown of tolerance facilitating
an autoimmune response.
This group identified a 12-amino acid residue peptide of
the inner domain of PDC-E2 containing the lipoic acid
cofactor carrying 173 lysine to elicit the strongest reactivity
of purified sera from PBC patients when compared to a
number of other potential epitopes. They subsequently
could show that reaction of the same PBC sera was
significantly increased by lipoylation of this epitope [193].
Subsequently, the identified PDC-E2 residue was mod-
ified by replacing lipoic acid with a series of similar but
distinct synthetic structures. Following this modification,
PDC-E2-specific autoantibodies from patients with PBC
reacted with higher affinity to the modified epitopes than to
the native PDC-E2 peptide. The structure inducing maximal
affinity was demonstrated to be derived from 2-nonynoic
acid, a compound widely used in cosmetics [116].
Xenobiotics, in studies of the same group, were also
shown to induce PBC-like features in different animal
models. Immunization of rabbits with 6-bromohexanoate
(6BH), coupled to bovine serum albumin (BSA), led to
break of tolerance to PDC-E2 as judged by the detection of
AMA [194]. In guinea pigs, immunization with the
compound 6BH–BSA led to the development of histolog-
ical lesions typical of autoimmune cholangitis with the
concurrent appearance of AMA, albeit with a long latency
of 18 months [195]. Most recently, these efforts resulted in
the development of an inducible animal model of PBC in
C57BL/6 mice. In these animals, 2-octynoic acid coupled to
BSA after a short follow-up of 8–12 weeks induced
manifest autoimmune cholangitis, typical AMA, increased
liver lymphoid cell numbers, an increase in CD8 liver-
infiltrating cells, and elevated levels of serum tumor
necrosis factor α and interferon γ. Remarkably, unlike
many other animal models of PBC, the reported immuno-
genic response was liver-specific, and no inflammation was
found in organs other than the liver [196]. However, the
model still has disadvantages, e.g., lacking the development
of fibrosis.
An alternative but complementary concept for loss of
self-tolerance in PBC is the idea of underlying immune
deficits. This concept is based on clinical and experimental
evidence. PBC exhibits clustering with various autoimmune
disorders, both within individuals and family. Moreover, in
PBC there are reduced levels of Tregs suppressing immune
reactions against self [197]. In two genetically manipulated
mouse strains, spontaneous occurrence of a PBC-like
lymphoid cholangitis together with positivity for anti-
PDC-E2 within several weeks of life was reported when
either transgenic expression of a dominant negative TGF-β
II receptor (dnTGF-β RII) or transgenic disruption of the
IL-2 receptor alpha that is highly expressed on Tregs was
performed [198, 199]. Interestingly, B cells had a suppres-
sive effect on the inflammatory response in the dnTGF-β
RII model of PBC [200]. A role for IL-2 signaling defects
in development of PBC was supported by a report of a
PBC-like liver disease in a child with inborn deficiency of
IL-2 receptor alpha [201]. An additional mouse model of
NOD.c3c4 was described to develop autoimmune biliary
disease and was found to test AMA-positive [202]. In all
models outlined here, the biliary epithelium is infiltrated
with CD4 and CD8 T cells, whereas granulomas and
eosinophilic infiltration are seen only in NOD.c3c4 mice.
Conversely, IL-17 has recently been shown to be
involved in various autoimmune disorders. In PBC liver
tissues, density of IL-17(+) CD4 lymphocytic infiltration
(Th17) was higher than in healthy liver. Although enhanced
density of Th17 cells is not specific to PBC, it is in line
with the observation of the decreased number of Tregs and
may illustrate the counterplay of Tregs and Th17 cells in
PBC [203].
Pathogenetic model
There has been impressive progress in unraveling pathoge-
netic factors of PBC over the past decade. In favor of a
genetic background, an outstanding concordance rate
among monozygotic twins has been identified, as well as
various genetic associations. Clustering of distinct HLA
alleles and, among others, allelic variations of TNFα,
CTLA-4, and anion exchanger 2 (AE2), respectively, have
been described. In addition, there is compelling evidence
for an environmental factor required for the development of
PBC. Xenobiotics capable of modulating mammalian
proteins to form neoantigens have been shown to induce
pathologies resembling PBC in animal models. Further-
more, various infectious agents have been associated with
PBC in humans, although direct experimental evidence for
their role in the pathogenesis is limited. Lastly, disruption
of AE2 [204] and genes involved in the regulation of
immune response, such as the TGF-β II or IL-2 receptor or
the AE2, gives rise to histologic and serologic changes
mimicking PBC in different animal models and may be
contributing to susceptibility for PBC in human.
However, a common causative pathway to PBC, if it
exists, could not yet be identified, and it is still controver-
sial which of the outlined factors predispose most to PBC.
It may well be speculated that the search for “the cause” of
PBC might lead into the dark, and the identified pathoge-
netic factors may contribute to a different extent in each
patient. Why should the cause of PBC not be variable as is
the clinical picture? The latter is highly variable: We define
PBC today as the presence of cholestasis and AMAs, but
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only 90–95% of patients are AMA-positive and some
AMA-positives hardly develop PBC. Most patients respond
to UDCA treatment, but one third does not and disease
progression is highly variable, to mention only the most
obvious variabilities. The clinical picture that, by conven-
tion, we call PBC may well emerge from an individual
composition of the described and other pathological factors.
Jones [84] suggested a model of PBC development
distinguishing “upstream” from “downstream” events.
“Upstream” in this model refers to the causes of BEC
loss, ductopenia and cholestasis, which are unique to PBC
(and probably unique to each individual patient) and
include genetic and toxic factors, infectious agents, and
immune-mediated events. “Downstream” of these initiating
mechanisms, nonspecific pathologic events occur resulting in
bile duct damage, hepatocyte injury, inflammation, and
fibrosis independently of the primary -individual variable-
cause. “Downstream” events such as hydrophobic bile salt
retention aggravate the underlying injury, further promoting
hepatic and cholangiocellular damage [205].
This pathogenetic model provides an explanation for the
limited efficacy of immunosuppressive drugs in PBC.
Agents such as prednisolone, in the treatment of PBC of
limited efficacy, may mainly affect upstream mechanisms.
In clinical trials, these agents have, however, largely been
evaluated in relatively advanced, symptomatic patients. In
these individuals, downstream processes may have become
predominant.
The balance of evidence in PBC remains strongly in
favor of an autoimmune process in which the autoreactive
attack is directed at epitopes within self-PDC-E2. The
following factors can, in principle, contribute to this
breakdown of self-tolerance and have been suggested for
PBC:
1. There is strong and compelling evidence to support
molecular mechanisms of cross-reactivity between the
PDC-E2 lipoic acid co-factor and environmental xeno-
biotics inducing auto-immunogenity of modified self-
PDC-E2. Animal modeling data would argue that a
cross-reactive B cell response induced to xenobiotic-
modified self-PDC can, through a process of epitope
spreading driven by antigen-specific cross-reactive B
cells, translate into the breakdown of T cell tolerance
responsible for the effector T cell mechanisms thought
to be directly responsible for BEC loss. The clinical
implication of this observation again is that immuno-
modulatory approaches to therapy should play a role
particularly in the earliest stages of PBC.
2. Alternatively or in addition, molecular mimicry mech-
anisms with cross-reactivity between self-PDC and
bacterial or potentially viral structures may support or
induce breakdown of tolerance.
3. Most data on genetic associations with disease point to
loci or genes involved in immune function. Altered
regulation of self-tolerance can possibly support or
induce immune reaction against self-PDC-E2, express-
ed normally or aberrantly by BECs.
4. Primary events of cholangiocellular apoptosis or cell
damage have been suggested that could lead to aberrant
presentation of self-antigens or create an inflammatory
environment potentially triggering immune dysregula-
tion. Suggested mechanisms include metabolic stress,
possibly triggered by dysfunction of transporters
involved in cell maintenance like AE2. This mecha-
nism was suggested [179] based on the finding that an
AE2 variant is a strong and independent prognostic
factor for disease progression in PBC under UDCA
therapy [112]. Furthermore, secretion of directly toxic
environmental compounds into the bile or viral infec-
tion would trigger cholangiocellular damage.
5. Finally, functional and morphological changes in
BECs, either as an associated process to outlined
factors or as part of the homeostatic mechanism
designed to retain BEC function, may lead to altered
self-recognition.
Each of these mechanisms may occur simultaneously or
sequentially and, to a variable extent, result in the
breakdown of tolerance and immune-mediated liver pathol-
ogy. Once an autoimmune reaction is initiated, various
vicious cycles are conceivable. Inflammatory reaction
secondary to loss of tolerance will lead to further
cholangiocellular damage and apoptosis, increasing presen-
tation of (altered) self-PDC and increase autoreactivity.
Once bile duct loss and cholestasis are established,
retention of bile salts and other toxic compounds perpetu-
ates damage to BECs and subsequently to the entire liver.
Maintenance of these vicious cycles may be supported by
an immune system that is genetically dysregulated and
insufficiently capable of suppressing autoimmune reactions.
The outstanding paradox in PBC pathogenesis remains
the tissue tropism of the immune attack on the small
intrahepatic bile ducts, although the mitochondrial targets
are ubiquitously expressed proteins. An increased vulnera-
bility of the primarily affected BECs therefore is a
prerequisite in the pathogenesis of PBC. Staining of BECs
from PBC livers with monoclonal antibodies against the
mitochondrial PDC-E2 autoantigen showed a specific
reaction at the apical surface which was not found in
controls [206, 207]. Other non-PBC-related mitochondrial
proteins show the expected cytoplasmic pattern [208]. It
was subsequently demonstrated that the apical staining is
due to a complex between (auto-)antimitochondrial IgA and
PDC-E2, giving rise to speculations that IgA might be a
player in the immune-mediated destruction of BECs [209,
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210]. Apoptosis of BECs has been proposed as a cause of
aberrant neoantigen presentation, responsible for activation or
attraction of autoreactive T lymphocytes or antibodies. Unlike
other cell types [211] for which autoantibody recognition of
PDC-E2 is abrogated during apoptosis, probably by gluta-
thiolation of the lysine–lipoyl moiety of PDC-E2, the
antigenicity of PDC-E2 persists in the apoptotic BECs in
which glutathiolation does not occur [211, 212].
The course of apoptotic markers in patients with PBC
peaks in the middle stages of the disease (stages II–III) rather
than in earlier stages. This could solely support a role of
apoptosis as a trigger for loss of self-tolerance, with probably
only a little number of cells being affected rather than being
the main initiating event in PBC. In a putative positive
feedback loop, apoptosis, autoreactive T cell response, chole-
static bile salt retention, and failed replicative homeostasis
may result in the destruction of BECs and bile duct structures.
Therapy
UDCA treatment
UDCA has been administered in Chinese traditional
medicine as a remedy for liver diseases and other disorders
in the form of black bear's bile since the time of the T'ang
dynasty (618–907AD) and was reestablished in the late
1950s in Japan as a choleretic agent with gallstone-
dissolving and anticholestatic properties. In the Western
literature, the beneficial effects of UDCA on serum liver
tests for patients with hepatic disorders were first reported
in the 1980s [213, 214], and UDCA has since been
established for the treatment of PBC. Today, it is the only
FDA-approved drug and standard therapy for PBC. UDCA
was shown to improve serum biochemical markers such as
bilirubin, AP, γGT, cholesterol, and IgM levels [215–220].
UDCA may slow down histologic progression to liver
cirrhosis [219, 221], improve quality of life, survival free of
transplant, and overall survival [11–14, 222]. It is safe and
side effects are few [223]. However, the mechanisms of
action of UDCA in chronic cholestasis remain enigmatic
[224]. About a third of patients is not sufficiently controlled
with UDCA monotherapy [12, 13], which drives the search
for additional therapeutic approaches (Fig. 1).
Pathophysiologic rationale for UDCA therapy
Cholestasis leads to retention of bile salts and other
potentially toxic constituents of bile not only systemically
but particularly in hepatocytes. This promotes hepatocellu-
lar damage and, in a chronic state, can induce the
development of fibrosis and cirrhosis of the liver.
Fig. 1 Summary of standard therapy and promising future therapeutic
options in PBC with respect to their action in the pathophysiologic
chain of PBC. UDCA in a dose of 13–15 mg per kg body weight per
day, administered in either one dose or divided into two adminis-
trations per day, is the only FDA-approved drug and the cornerstone in
PBC therapy. Liver transplantation (LTx) is performed for liver failure
in end-stage disease. The most advanced database for future
therapeutic consideration is available for budesonide. Though specu-
lative, current preliminary data suggest a future role for agonists to
certain nuclear receptors: peroxisome proliferator activated receptor
alpha (PPARα), farnesoid x receptor (FXR), vitamin D receptor
(VDR), pregnane x receptor (PXR), and constitutive androstane
receptor (CAR)
294 Semin Immunopathol (2009) 31:283–307
As recently summarized by Paumgartner and Pusl [225],
the general biochemical and physiologic principles in treating
cholestatic liver disease can be broken down to “(1) reduction
of hepatocellular uptake of bile salts and other organic anions;
(2) stimulation of the metabolism of hydrophobic bile salts
and other toxic compounds to more hydrophilic and less toxic
metabolites; (3) stimulation of orthograde secretion into bile
and (4) stimulation of retrograde secretion of bile salts and
other potentially toxic cholephils into the systemic circulation
for excretion by the kidney; (5) protection of injured
cholangiocytes against toxic effects of bile salts; (6) inhibition
of apoptosis caused by elevated levels of bile salts; and (7)
inhibition of fibrosis” [225].
Treatment with UDCA addresses most of these postu-
lated principles as recent clinical and experimental data
suggest [224, 226, 227]. Still, no relevant effect of UDCA
on (1) bile salt uptake and (2) bile salt metabolism [228,
229] has been demonstrated in man.
Hepatic secretion When patients with PBC are treated with
UDCA, serum levels of bilirubin [216] and endogenous bile
salts [230] decrease. This effect of UDCA seems to be
mediated by posttranscriptional rather than transcriptional
mechanisms, as mRNA levels of key transporters like the
conjugate export pump, ABCC2/MRP2, and the bile salt
export pump, ABCB11/BSEP, are not affected by UDCA in
man. Enhanced hepatic protein levels of BSEP, but notMRP2,
have been observed under UDCA treatment in patients with
gallstones [228] and may contribute to improved elimination
of bile salts [231]. In an animal model of cholestasis, UDCA
increases the density of Bsep and Mrp2 in the canalicular
membrane of the rat by stimulating transporter targeting and
insertion into the membrane [232] by a cooperative protein
kinase C α/protein kinase A-dependent mechanism [224,
233–235]. An integrin-dependent dual signaling pathway
involving mitogen-activated protein kinases (MAPK) Erk 1/2
and p38MAPK has been shown to mediate UDCA-induced
canalicular BSEP insertion in normal [236, 237], but not
cholestatic [238] hepatocytes. Whether UDCA-induced
kinase-mediated phosphorylation of carriers contributes to
enhanced canalicular transporter density and activity needs to
be studied in more detail [224, 235, 239].
Dilution of bile and the flushing of bile ducts were
postulated as important functions of cholangiocellular bile
formation [225]. In PBC, expression of the hepatic AE2
and biliary bicarbonate secretion by AE2 are impaired [240,
241]. UDCA stimulates both AE2 expression [242] and
bicarbonate secretion [241].
Retrograde secretion of bile salts and other potentially
toxic cholephiles As an adaptive mechanism during chole-
stasis, basolateral conjugate transporters such as ABCC3/
MRP3 are upregulated and cholephiles such as bilirubin
glucuronides, which are not adequately secreted into bile,
can leave the liver cell via the basolateral route. In contrast
to the postulated increase in retrograde secretion [228],
UDCA diminishes basolateral efflux due to the effective
stimulation of orthograde secretion of potentially toxic
compounds into the bile.
Protection of cholangiocytes Bile, with its high concentra-
tion of hydrophobic bile salts, exhibits extracellular
cytotoxicity in vitro, but does not cause cholangiocyte
injury under physiological conditions. In PBC, inflamma-
tory bile duct injury may be aggravated by hydrophobic
bile salts. Two mechanisms have been discussed by which
UDCA protects the biliary epithelium against toxic effects
of bile, i.e., relative reduction of hydrophobic bile salts and
enrichment of phospholipids in bile. When administered at
recommended doses of 13 to 15 mg/kg/day, UDCA content
may rise up to 50% of total bile salts [243] and to an even
higher percentage when the dose of UDCA is increased
[244, 245]. In consequence, bile composition is shifted
towards less toxic and less hydrophobic bile salts.
UDCA administration in patients with gallstones
increases expression of MDR3, a phospholipid flippase, in
the liver [228]. This might explain the stimulation of biliary
phospholipid secretion by UDCA, as described in patients
with PSC [246]. Secreted phospholipids form mixed
micelles with bile salts, thereby mitigating their toxic
effects on cholangiocytes.
Inhibition of apoptosis Hydrophobic bile salts induce
hepatocellular apoptosis [247–249] by death receptor-
dependent [250, 251] and -independent [252, 253] mech-
anisms, an effect that may become relevant when bile salts
accumulate in the liver in cholestatic states. UDCA exerts
anti-apoptotic effects in experimental in vivo models [247,
249, 252] as well as in vitro in primary human hepatocytes
[254]. This anti-apoptotic effect may contribute to the
alleviation of liver injury during UDCA treatment.
Inhibition of fibrosis Release of chemokines and cytokines
by injured cholangiocytes and infiltrating inflammatory
cells [255] as well as hepatic stellate cell proliferation
induced by bile salts may play a role in fibrogenesis [256].
UDCA has been reported to delay development of severe
fibrosis and cirrhosis in PBC [221]. This may be related to
the aforementioned anticholestatic and anti-apoptotic
effects rather than direct antifibrotic effects of UDCA.
The bile salt derivatives 6-ethyl CDCA (6-ECDCA) and
nor-UDCA inhibit fibrosis in the bile-duct-ligated mouse.
While 6-ECDCA seems to mediate this antifibrotic effect
via farnesoid X receptor (FXR) and small heterodimer
partner (SHP) [257], the mechanism of action of nor-
UDCA remains yet unclear [258].
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Immunomodulatory properties of UDCA have been con-
troversially discussed in the past [259–262]. The glucocor-
ticoid receptor in rat hepatocytes is activated by UDCA in a
ligand-independent way, whereas suppression of IFN-γ-
induced MHC class II expression was found to be
glucocorticoid-receptor-dependent [263]. It remains to be
defined whether glucocorticoid receptor activation is unique
to UDCA, and thus therapeutically relevant, or might be
shared by endogenous bile salts.
Comprehensive reviews on molecular actions of UDCA
have been published in the recent past [205, 224, 264–266].
UDCA treatment in clinical practice
UDCA is currently considered the mainstay of therapy for
PBC [28, 29]. Randomized, double-blinded, placebo-
controlled trials have consistently shown that UDCA, admin-
istered today in standardized doses of 13 to 15 mg/kg/day,
improves serum biochemical markers including bilirubin
[215–218, 220], an important prognostic marker in PBC
[267]. A number of studies demonstrated an improvement of
histological features by UDCA. In a combined analysis of
four clinical trials including a total of 367 patients [268] and
in an independent in 103 patients [221], UDCA therapy was
associated with delayed progression and a marked decrease
in progression rate from early-stage disease to late histologic
stages. Despite these effects on disease progression and
severity, the assessment of the effect of UDCA treatment on
long-term survival has been more difficult. A combined
analysis of three randomized controlled trials including 548
patients in total treated with UDCA for up to 4 years
revealed improved survival free of liver transplantation in
patients with moderate or severe disease [222]. Another
combined analysis of five studies, all with a follow-up of at
least 4 years, quantified the reduction in the risk of death or
liver transplantation in patients treated with UDCA to 32%
[269]. A long-term follow-up study in a cohort of 225
patients, in part overlapping with the aforementioned
analyses, reported 10-year survival without liver transplan-
tation to be significantly higher in UDCA-treated patients
compared with survival predicted by the Mayo model [270].
Recent long-term trials from France, Spain, and The
Netherlands have shown comparable results [11–13, 271].
The survival rate of patients in early stages of the disease
who biochemically responded to therapy was similar to that
in the control populations. “Response” here is defined as a
decrease in AP to <40% of pretreatment levels or normal-
ization at 1 year (Barcelona criteria) [12] or serum bilirubin
<1 mg/dl, AP≤3 × N and AST≤2 × N after 1 year of UDCA
treatment (Paris criteria) [13, 14]. An additional non-
randomized controlled study from Greece confirmed that in
most patients with PBC treated with UDCA (particularly
those who are in early stage of disease), the 10-year survival
is comparable to that in the general population [272]. Despite
these intriguing findings, the beneficial effects of UDCA on
survival have repeatedly been questioned: A large random-
ized Swedish trial failed to confirm an effect of UDCA on
disease progression and survival at a dose of approximately
8 mg/kg/day [273]. It was concluded from this and other
studies that doses of UDCA lower than 10 mg/kg/day are of
little benefit. In the follow-up of patients in a US [274] and a
Canadian trial [217], UDCA had no significant influence on
incidence of endpoints liver transplantation or death. Also, a
meta-analysis of 11 randomized trials could not confirm a
significant effect of UDCA on survival and incidence of liver
transplantation [275]. In this meta-analysis, however, six
studies with only 2 years of follow-up were included, as
were two studies administering UDCA at low doses of
10 mg/kg/day or less. Other meta-analyses suffered from
similar shortcomings [276, 277] and may therefore have
missed a beneficial effect of UDCA. Accordingly, meta-
analyses which only included long-term trials with follow-
up of at least 2 years and those using an effective dose of
UDCA of more than 10 mg/kg/day verified that treatment
with UDCA significantly improves quality of life and
transplant-free survival and delays histologic progression
in early-stage patients [278, 279]. Current guidelines
therefore recommend to treat PBC with UDCA using
doses of 13 to 15 mg/kg/day and to start treatment early
[28, 29, 280].
About two thirds of patients treated according to these
recommendations respond adequately as defined by the
Barcelona or the Paris criteria and may have a normal life
expectancy. The most recent study from The Netherlands
comprising 375 patients with a mean follow-up of 9.7 years
again stressed the importance of early treatment showing a
clear survival benefit for patients treated in early stages of
disease with normal serum bilirubin and albumin levels at
the start of therapy [14].
For the remaining one third of patients who fail to
achieve biochemical response according to Paris and
Barcelona criteria or who are at an advanced histological
stage at start of medical treatment, therapeutic options are
limited to date and novel approaches are needed.
Immunosuppressive drugs
Corticosteroids and other immunosuppressive agents have
been evaluated for therapeutic use in PBC. In a 3-year,
placebo-controlled trial including 36 patients with PBC,
prednisolone significantly improved serum AP levels, IgGs,
and AMA and diminished deterioration of liver histology,
whereas bone loss was aggravated [281]. Combination of
UDCA and prednisolone in comparison to UDCA alone
resulted in a significant improvement of histological
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features [282]. It is yet unclear whether increased expres-
sion of AE2 isoforms contributes to the beneficial effect of
combined treatment with UDCA and corticosteroids in
PBC. Experimentally, enhanced expression of alternative
AE2 isoforms and enhanced transport capacity for bicar-
bonate in human cholangiocytes and in a hepatocyte cell
line were demonstrated [283]. AE2 expression and biliary
bicarbonate secretion is usually diminished in PBC [241].
Serious side effects of long-term glucocorticoid treat-
ment may outweigh the potential benefit. In this respect, the
introduction of budesonide, a nonhalogenated corticosteroid
with an extensive first-pass metabolism has been a
promising innovation. A 2-year controlled double-blinded
trial included 39 patients with early-stage PBC and
compared treatment with UDCA plus budesonide against
UDCA plus placebo. Combination therapy improved
biochemical and histological features and reported only
few corticosteroid-related side effects [284]. These promis-
ing results, however, could not be confirmed in a
subsequent study from the Mayo Clinic. Here, adding
budesonide for 1 year in 22 patients with suboptimal
response to UDCA alone had only marginal effects on
serum bilirubin and AP levels. In contrast, the Mayo risk
score increased and there was a significant worsening of
osteoporosis [285]. This open trial, however, included late-
stage patients, which may in part explain the disappointing
results. As found in a short-term pharmacokinetic study,
administration of budesonide to cirrhotic PBC patients leads
to high plasma levels of budesonide associated with serious
adverse effects and should therefore be avoided [286]. A
Finish study [287] included only patients with stages I to III
(n=77) in a 3-year randomized trial and used a lower dose of
budesonide. The effects of budesonide plus UDCA were
compared to UDCA alone. A significant improvement of
histological features was observed in the combination group
on top of the beneficial biochemical effects of UDCA alone.
Long-term controlled trials are required to define whether
combination of UDCA with budesonide provides a signifi-
cant benefit in patients with early-stage PBC inadequately
responding to UDCA monotherapy.
Other immunosuppressive agents including azathioprine,
cyclosporine, mycophenolate mofetil, or methotrexate and
drugs with antifibrotic properties including penicillamine,
colchicine, and silymarin have not been shown to markedly
improve the natural course of the disease or were associated
with significant toxicity during long-term treatment [1,
288–296].
Novel pharmacologic approaches
Novel concepts for medical therapy of PBC, alone or in
combination with UDCA, have recently been considered
particularly for use in patients with incomplete response to
UDCA. Among others, antiretroviral, immunomodulatory,
and antioxidant approaches were evaluated.
A human betaretrovirus has been controversially debated
as a potential pathogen in PBC as outlined above. An
antiretroviral strategy has therefore been tested in PBC:
Lamivudine in combination with zidovudine (Combivir)
normalized AP and reduced bile duct injury in a 1-year
pilot trial including 11 patients [150]. This finding still
awaits confirmation by a randomized, placebo-controlled
study.
The peroxisome proliferator-activated receptor α
(PPARα) agonist bezafibrate was reported to improve
serum liver tests in PBC [297] and should undergo more
extensive evaluation in patients with PBC with an incom-
plete response to UDCA.
Future anticholestatic strategies in PBC are targeted
towards stimulation of transcription of key hepatocellular
and cholangiocellular transporters in order to improve the
secretory capacity of the cholestatic liver. First results of
pilot studies using the FXR agonist 6-ECDCA are eagerly
awaited.
Therapy of extrahepatic manifestations
Pruritus
UDCA is an accepted treatment of cholestatic pruritus in
ICP (intrahepatic cholestasis of pregnancy). However, its
effect on pruritus is variable in PBC [217]. At present, no
convincing data for an antipruritic effect of UDCA in PBC
are available [298].
Both peripherally acting pruritogens and central nervous
dysfunction have been implicated in the pathogenesis of
cholestatic pruritus [9]. According to these two concepts,
most therapeutic interventions currently under study for
cholestatic pruritus are either directed towards elimination
of so far undefined pruritogens or modulation of central
neurotransmission. The pharmaceutic options currently
recommended include [29]: (1) anion exchange resins, such
as cholestyramine and colestipol, which bind anions and
amphipathic molecules and reduce their intestinal absorp-
tion and systemic accumulation. Despite extensive clinical
experience, suggesting a beneficial effect in up to 90% of
patients, no large clinical trials have evaluated the efficacy
of exchange resins [298]. In patients lacking adequate
improvement, treatment with (2) rifampicin may be helpful
[298–301]. Rifampicin is a semisynthetic antibiotic and as a
potent pregnane X receptor (PXR) agonist leads to the
induction of hepatic microsomal enzymes. Thereby, it may
promote metabolism of potential pruritogens. As a third-
line option, (3) opioid antagonists (naloxone, nalmefene,
naltrexone) have been found to reduce itch severity in
patients with PBC [298, 302–304]. (4) The selective
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serotonin reuptake inhibitor sertraline [305, 306] has been
reported to improve cholestatic pruritus in small clinical
trials and has most recently been considered as a fourth-line
treatment option [29, 280]. Other experimental approaches
include 5-hydroxytryptamine receptor type 3 antagonists,
cannabinoids, subhypnotic doses of propofol, plasmaphe-
resis, albumin dialysis, and nasobiliary drainage in desper-
ate cases, although adequate trials are lacking [29, 63].
Liver transplantation should be considered in serious cases
in which all other strategies have failed, even if liver
function is still conserved [29].
Fatigue
Specific medical therapies of fatigue associated with
chronic cholestasis have not yet been defined. UDCA
treatment seems to have no or limited beneficial effects on
fatigue in PBC [217, 307]. Oral supplementation with
antioxidants showed promising results in a pilot study, but
had no beneficial effect in a randomized, placebo-
controlled, crossover trial [308]. Independent of the
underlying disease, altered serotoninergic neurotransmis-
sion has been implicated in the development of fatigue
[309]. The 5-HT3 serotonin receptor antagonist ondanse-
tron, however, did not significantly reduce fatigue com-
pared with placebo in a randomized, placebo-controlled
trial [310]. The selective serotonin reuptake inhibitors
fluvoxamine and fluoxetine also failed to exert beneficial
effects on fatigue in this patient group [311, 312].
In a series of 21 PBC patients with excessive daytime
sleepiness [313], the centrally acting agent modafinil was
investigated in an open-label study [314]. Significant
improvement was seen in Epworth Sleepiness Scale scores
and fatigue severity as assessed by PBC-40 fatigue domain
score, but the drug had to be stopped due to side effects in
a considerable part of the patients before the end of the
study.
In contrast to pruritus, fatigue may not improve
significantly following liver transplantation.
Metabolic bone disease
Independent of the etiology, bone mineral loss is a
recognized complication of cholestatic liver diseases. In
PBC, it moderately increases absolute and relative fracture
risk compared to the general population [315, 316].
Treatment of the underlying liver disease with UDCA does
not prevent bone loss in PBC [317, 318]. Calcium and
vitamin D supplementation is usually recommended in
osteoporosis, although their role in preventing osteoporosis
and fracture in chronic liver disease is unclear [319, 320].
Alternative interventions to prevent and treat osteoporosis
in liver disease have only been tested in a few studies.
Parenteral calcitonin, tested in one controlled trial for
6 months, was ineffective in halting bone loss in patients
with PBC [321], whereas hormone replacement therapy
was demonstrated to improve vertebral bone density in
PBC [319, 322, 323]. In large clinical trials, however,
hormone replacement therapy was associated with serious
side effects, including the risks of breast cancer, coronary
artery disease, and thromboembolism, limiting its use for
the prevention of fractures in osteoporosis [324–326].
Use of bisphosphonates is controversial. In a placebo-
controlled trial, cyclical etidronate did not significantly
improve bone density [327]. Also, a 4-year treatment with
clodronate plus calcium/vitamin D did not improve osteo-
penia in women with PBC in a prospective study [328]. In
two controlled trials however, alendronate significantly
improved spine and femoral bone mineral density com-
pared with placebo and had greater antiresorptive activity
than etidronate [329, 330].
According to current guidelines [29], supplementation
with calcium (1,000–1,200 mg/day) and vitamin D (400–
800 IU/day), though not evidence-based, should be
considered in all patients with cholestatic liver disease.
Alendronate or other bisphosphonates are recommended
at a T score < −2.5 (DEXA) or following pathological
fracture.
Liver transplantation
Liver transplantation is the treatment of choice in patients
with late-stage PBC. Indications are decompensated cirrho-
sis with treatment-resistant ascites, recurrent spontaneous
bacterial peritonitis, encephalopathy, recurrent variceal
bleeding, or hepatocellular carcinoma. In highly selected
patients (see above), treatment-resistant pruritus in the
absence of decompensated cirrhosis may be an indication
for transplantation, and so is severe osteoporosis [28, 331].
Survival rates of 80% to 90% at 5 years have been reported.
The disease recurs in up to 30% at 10 years after
transplantation, but then usually displays a mild course
under immunosuppressive treatment [331].
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